On March 25, 2025 Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, reported the company’s new name: Ernexa TherapeuticsSM (NASDAQ: ERNA). The new name reflects the company’s laser-focused mission and ambitious vision.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Eterna Therapeutics began as a pioneer developing an innovative and differentiated cell therapy platform alone, but today, we have entered a new era of evolution and growth," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "We are an organization with a new strategic focus, one that is advancing transformative cell therapy products with real clinical potential, directly impacting patients’ lives and addressing unmet medical needs."
Ernexa’s technology transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which are a specialized type of stem cell that has a unique ability to migrate toward tumors or inflammation. Ernexa’s allogeneic synthetic iMSCs allow for enhanced predictability at scale, helping to avoid the challenges of immune rejection and donor shortages.
Ernexa has two cell therapy products in development, which are undergoing preclinical trials. Its lead cell therapy product, ERNA-101, is engineered to enhance and regulate the immune system’s response, enabling it to identify and eliminate cancer cells. ERNA-102 is designed to combat inflammation and treat autoimmune disease.
ERNA-101 is being developed for the treatment of ovarian cancer as its first indication. There is a significant unmet need in ovarian cancer, which currently lacks highly effective, widely applicable targeted therapies. Many patients develop resistance to the standard treatment in ovarian cancer – platinum-based chemotherapy. Other treatments have been developed but with little success.
ERNA-101 and ERNA-102 have the potential to bring significant hope in the treatments of ovarian cancer and autoimmune disease, respectively.
Ernexa’s ticker symbol will remain as ERNA.
(Press release, Eterna Therapeutics, MAR 25, 2025, View Source [SID1234661059])